ArticleAmerican journal of cancer research2025
Study on serum tRF-30-RRJ89O9NF5W8 as a potential biomarker for clinical diagnosis of gastric cancer.
Article in American journal of cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer (GC) is one of the leading causes of cancer-related deaths worldwide. In this study, our objective was to identify a specific tRNA-derived small RNA (tsRNA) as a biomarker for GC. We developed and validated a methodology to detect the expression level of tRF-30-RRJ89O9NF5W8 in the serum of GC patients. The results showed that the expression of tRF-30-RRJ89O9NF5W8 was significantly downregulated in the serum of GC patients and increased after radical surgery. Clinicopathological correlation analysis revealed that its expression level was closely associated with TNM stage, T stage, and neural/vascular invasion. Compared with existing GC diagnostic markers, tRF-30-RRJ89O9NF5W8 demonstrated superior diagnostic performance, effectively distinguishing GC patients from those with gastritis and healthy controls. These findings suggest that tRF-30-RRJ89O9NF5W8 may serve as a promising candidate diagnostic biomarker for GC and provide theoretical support for its potential as a therapeutic target.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.